treatment

MDS and AML Research Summaries for Patients from the 2020 European Hematology association and the American Society of Clinical Oncology Meetings

SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH)

VOYDEYA is a prescription medicine used along with ravulizumab or eculizumab to treat breakdown of red blood cells that takes place outside of blood vessels (extravascular hemolysis), in adults with paroxysmal nocturnal…

ULTOMIRIS® is a prescription medicine called a monoclonal antibody. ULTOMIRIS® is used to treat adults and children 1 month of age and older with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH)

Venclexta® (also known as Venetoclax) is a prescribed oral tablet approved by the Food and Drug Administration for adult patients with acute myeloid leukemia (AML)

RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor used to treat adults with IPSS-R low to intermediate-1 myelodysplastic syndromes (MDS) with transfusion dependent anemia requiring four or more red blood…

TIBSOVO is a prescribed medication approved to treat adult patients with myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation either when the disease has relapsed or has not improved after…

REBLOZYL® (luspatercept-aamt) was the first erythroid maturation agent (EMA) approved in 2020 by the Food and Drug Administration for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) who…

INQOVI® (previously known as ASTX727) is a prescribed oral tablet combination of decitabine and cedazuridine approved by the Food and Drug Administration for adult patients with myelodysplastic syndromes (MDS) and…

FABHALTA, a complement factor B inhibitor, is the first oral medication approved to treat adults with paroxysmal nocturnal hemoglobinuria (PNH)